Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal duration of oxaliplatin in adjuvant XELOX for gastric cancer
NCT04787354Phase 3Recruiting
- Sponsor
- Hallym University Medical Center
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin in gastric cancer (GC), sponsored by Hallym University Medical Center. Started Nov 2021; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04787354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787354.